Department of Pharmacy, Cleveland Clinic, Cleveland, OH.
Department of Pharmacy, Cleveland Clinic, Cleveland, OH
Cleve Clin J Med. 2024 Sep 4;91(9 suppl 1):S11-S18. doi: 10.3949/ccjm.91.s1.03.
In 2023 and 2024, 3 vaccines were approved by the US Food and Drug Administration (FDA) against respiratory syncytial virus (RSV) in adults. In addition, the first long-acting RSV monoclonal antibody for infants and young children was approved. This review provides clinicians with practical guidance to navigate this new era of RSV prevention.
在 2023 年和 2024 年，美国食品和药物管理局（FDA）批准了 3 种针对成人呼吸道合胞病毒（RSV）的疫苗。此外，还批准了第一种用于婴儿和幼儿的长效 RSV 单克隆抗体。这篇综述为临床医生提供了实用的指导，以应对 RSV 预防的新时代。
